| Year | Q2 2024 | Q1 2024 |
|---|---|---|
| Total Revenue | 5.89B | 5.63B |
| Cost of Revenue | 3.26B | 3.07B |
| Gross Profit | 2.62B | 2.56B |
| Operating Expenses | 878.6M | 933.1M |
| Research and Development | 0 | 0 |
| Selling, General & Administrative Expenses | 878.6M | 933.1M |
| Selling & Marketing Expenses | 0 | 0 |
| General & Administrative Expenses | 0 | 0 |
| Other Expenses | 0 | 418.4M |
| Operating Income | 1.74B | 1.63B |
| Total Other Income/Expenses Net | 409.7M | 397.3M |
| Income Before Tax | 2.15B | 2.03B |
| Income Tax | 568.8M | 519.1M |
| Net Income | 1.58B | 1.51B |
| Basic EPS | 34.61 | 32.94 |
| EPS Diluted | 34.61 | 32.94 |
| Basic Average Shares | 45.75M | 45.75M |
| Diluted Average Shares | 45.75M | 45.75M |
| EBITDA | 2.32B | 1.77B |
Pfizer Limited
PFIZER.NS
NSE
4080.25INR45.35 (1.12%)
PFIZER.NS Financial Statements
Retained Earning Schedule
| Year |
|---|
| Retained Earnings (Previous Year) |
| Net Income |
| Stock Repurchases |
| Dividend Paid |
| Retained Earnings |
| Other Distributions |
PPE Schedule
| Year |
|---|
| Gross PPE |
| Annual Depreciation |
| Capital Expenditure |
| Net PPE |
Intangible and Goodwill Schedule
| Year |
|---|
| Acquisitions and Adjustments |
| Goodwill (Previous Year) |
| Goodwill |